Programs & Current Stages
LurexBio maintains a deep and expanding intellectual property portfolio encompassing multiple complementary technology families. This layered approach protects core innovations across immune engineering, delivery systems, and manufacturing methods, establishing a strong foundation for future clinical and commercial development. The following overview outlines the progress and current standing of our active programs.
NeoTag™
Immune Tagging of Tumor Surfaces
Non-genetic display of multivalent pathogen-derived epitopes to trigger existing memory T-cell/NK responses.
Atraxis™
Membrane-Fusion Signal Deposition
Vesicle-mediated fusion to decorate tumor membranes with synthetic immune signals for adaptive/innate clearance.
Atraxis-X™
Expanded modality & logic controls for selective fusion, payload co-delivery, and orientation-controlled display.
DeltaGate Logic™
Δt-gated deposition windows & logic trees enable selective signal display and combinatorial immune engagement.
Our Platforms
Our platform architecture form a modular architecture that transforms immune-silent tumors into visible, targetable cells while maintaining precision, safety, and scalability across multiple disease categories.
Milestones to PCT & U.S. Conversions
Disclaimer: The development stages, milestones, and target dates presented on this page are forward-looking estimates for planning visibility only. They do not represent guarantees of completion or regulatory approval. Certain technical descriptions are generalized to protect proprietary and confidential information contained in pending patent applications. Actual timelines may differ materially based on scientific findings, intellectual-property strategy, counsel review, and collaboration schedules. Nothing herein constitutes an offer to sell or a solicitation to buy securities or products of Lurex Bio Inc.
Dec 2025
Claims matrix v2 + counsel redlines
Status: Complete
Deliverable: Consolidate claims; add fallback/defensive catch-alls.
Jan 2026
Partner MOUs & CRO shortlist
Status: Complete
Deliverable: Lock collaboration intents; define preclinical plan contours.
Feb 2026
Draft PCT framework & spec integration plan
Status: Planned
Deliverable: Unify background, figures, definitions; set ePCT workspace.
Mar 2026
First-pass PCT drafts (NeoTag/Atraxis family)
Status: Complete
Deliverable: Embed prophetic examples, orientation/density, Δt windows, selectivity ratios.
Apr 2026
Attorney review + figure finalization
Status: Complete
Deliverable: Resolve dependencies; finalize drawings & captions; prep ADS data.
May 2026
Final sign-offs, ePCT setup, fees & filings pack
Status: Complete
Deliverable: Verified PDFs, declarations, assignments; calendar national phase windows.
June 2026
File PCT + U.S. non-provisional conversions
Status: In Progress - Deadline
Deliverable: Submit via ePCT & USPTO; update portfolio map (post-filing). (Self-funded corporate IP milestone, independent of grant awards)